Europe Now a Growth Priority for North American Cannabis Capital
North American institutional cannabis investors now see the European medical market as a crucial driver of growth, a new survey suggests.
North American institutional cannabis investors now see the European medical market as a crucial driver of growth, a new survey suggests.
Today’s visit by Prime Minister Michael Kretschmer, part of the CDU, a party known for its critical stance on cannabis, to Grünhorn in Leipzig marks a significant milestone in the political recognition of cannabis as a plant-based medicine.
Written by Ben Stevens and Sarah Sinclair. 2024 has been a dramatic year for the global cannabis industry, seeing both historic steps forward and concerning regressions in both attitudes and policy.
While little common ground was found during Friday’s debate, the well-trodden rhetoric from each side emphasised that the implementation of CanG remains a controversial and divisive issue in Germany.
Last month, Germany’s Federal Joint Committee (G-BA) proposed significant changes to the medical cannabis prescription process, opening the door for medical cannabis to be prescribed via statutory health insurance (gesetzliche Krankenversicherung or GKV) This would enable around 70% of practicing German physicians to prescribe medical cannabis without prior approval from health insurance companies, which would…
Germany’s Federal Joint Committee (G-BA) last week proposed significant changes to the medical cannabis prescription process, set to have a major impact on the country’s already booming market.
In the course of the legalization of medical cannabis in Ukraine, Viktor Liaschko visited Germany’s largest cannabis network Grünhorn to find out how it works.